JP2023082080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023082080A5 JP2023082080A5 JP2023051686A JP2023051686A JP2023082080A5 JP 2023082080 A5 JP2023082080 A5 JP 2023082080A5 JP 2023051686 A JP2023051686 A JP 2023051686A JP 2023051686 A JP2023051686 A JP 2023051686A JP 2023082080 A5 JP2023082080 A5 JP 2023082080A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- nanoparticles
- vaccine composition
- composition according
- signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 14
- 229960005486 vaccine Drugs 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 230000011664 signaling Effects 0.000 claims 7
- 206010027476 Metastases Diseases 0.000 claims 6
- 208000037819 metastatic cancer Diseases 0.000 claims 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 230000005865 ionizing radiation Effects 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 101001057748 Human cytomegalovirus (strain AD169) Uncharacterized protein IRL7 Proteins 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(iv) oxide Chemical compound O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 claims 2
- 229940127130 immunocytokine Drugs 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 239000003970 toll like receptor agonist Substances 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108700010013 HMGB1 Proteins 0.000 claims 1
- 101150021904 HMGB1 gene Proteins 0.000 claims 1
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101001057744 Human cytomegalovirus (strain AD169) Uncharacterized protein IRL9 Proteins 0.000 claims 1
- -1 IFNγ Proteins 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 102100021592 Interleukin-7 Human genes 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 229940127145 L19-IL2 immunocytokine Drugs 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 1
- 206010006007 bone sarcoma Diseases 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 229950007409 dacetuzumab Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229950004003 fresolimumab Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical group C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 229950004563 lucatumumab Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 238000011375 palliative radiation therapy Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009571 retroperitoneal cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000037964 urogenital cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305810.2 | 2015-05-28 | ||
| EP15305810 | 2015-05-28 | ||
| JP2017561738A JP2018516256A (ja) | 2015-05-28 | 2016-05-27 | 治療用ワクチンとしての使用のためのナノ粒子 |
| PCT/EP2016/061989 WO2016189125A1 (en) | 2015-05-28 | 2016-05-27 | Nanoparticles for use as a therapeutic vaccine |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561738A Division JP2018516256A (ja) | 2015-05-28 | 2016-05-27 | 治療用ワクチンとしての使用のためのナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023082080A JP2023082080A (ja) | 2023-06-13 |
| JP2023082080A5 true JP2023082080A5 (enExample) | 2023-10-17 |
| JP7570134B2 JP7570134B2 (ja) | 2024-10-21 |
Family
ID=53298299
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561738A Pending JP2018516256A (ja) | 2015-05-28 | 2016-05-27 | 治療用ワクチンとしての使用のためのナノ粒子 |
| JP2023051686A Active JP7570134B2 (ja) | 2015-05-28 | 2023-03-28 | 治療用ワクチンとしての使用のためのナノ粒子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561738A Pending JP2018516256A (ja) | 2015-05-28 | 2016-05-27 | 治療用ワクチンとしての使用のためのナノ粒子 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11096962B2 (enExample) |
| EP (1) | EP3302419A1 (enExample) |
| JP (2) | JP2018516256A (enExample) |
| KR (1) | KR102727195B1 (enExample) |
| CN (2) | CN118286421A (enExample) |
| AR (1) | AR104806A1 (enExample) |
| AU (2) | AU2016269146B2 (enExample) |
| BR (1) | BR112017025553A2 (enExample) |
| CA (1) | CA2987331A1 (enExample) |
| EA (1) | EA201792560A1 (enExample) |
| HK (1) | HK1246160A1 (enExample) |
| IL (1) | IL255853B (enExample) |
| MA (1) | MA43100A (enExample) |
| MX (2) | MX2017015424A (enExample) |
| NZ (1) | NZ738527A (enExample) |
| TW (2) | TWI873079B (enExample) |
| UA (1) | UA124572C2 (enExample) |
| WO (1) | WO2016189125A1 (enExample) |
| ZA (1) | ZA201708686B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3424533A1 (en) * | 2017-07-05 | 2019-01-09 | Nh Theraguix | Methods for treating tumors |
| CN109010828B (zh) * | 2018-10-12 | 2020-10-20 | 中国科学院高能物理研究所 | 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途 |
| CA3115677A1 (en) | 2018-10-19 | 2020-04-23 | University Of Rochester | Immune modulators in combination with radiation treatment for advanced pancreatic cancer |
| AU2021374754A1 (en) * | 2020-11-05 | 2023-06-22 | Nanobiotix | Compositions of nanoparticles for treatment of cancer |
| CN120417926A (zh) | 2022-12-12 | 2025-08-01 | 纳米生物技术公司 | 用作放射增敏剂或用于可视化生物组织的新型金属氧化物纳米颗粒及其组合物 |
| CN116370625B (zh) * | 2023-03-14 | 2024-10-11 | 浙江大学 | 一种哑铃状的金-氧化铈纳米材料的制备方法及其产品和应用 |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4280918A (en) | 1980-03-10 | 1981-07-28 | International Business Machines Corporation | Magnetic particle dispersions |
| US4672040A (en) | 1983-05-12 | 1987-06-09 | Advanced Magnetics, Inc. | Magnetic particles for use in separations |
| US4770183A (en) | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US6099457A (en) | 1990-08-13 | 2000-08-08 | Endotech, Inc. | Endocurietherapy |
| US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
| CA2137145A1 (en) | 1992-06-08 | 1993-12-23 | Mark S. Chagnon | Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications |
| WO1994002068A1 (en) | 1992-07-21 | 1994-02-03 | The General Hospital Corporation | System of drug delivery to the lymphatic tissues |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| JP2930421B2 (ja) | 1994-02-28 | 1999-08-03 | メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物、その製造方法及びその使用方法 |
| GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
| JPH10120597A (ja) | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
| WO1998040049A2 (de) | 1997-03-07 | 1998-09-17 | Max-Delbrück-Centrum für Molekulare Medizin | Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung |
| DE19716732C2 (de) | 1997-03-07 | 1999-03-25 | Max Delbrueck Centrum | Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE19726282A1 (de) | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
| US6161034A (en) | 1999-02-02 | 2000-12-12 | Senorx, Inc. | Methods and chemical preparations for time-limited marking of biopsy sites |
| US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US6645464B1 (en) | 1998-07-30 | 2003-11-11 | James F. Hainfeld | Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy |
| AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
| EP2343047B2 (en) | 2000-02-08 | 2021-03-17 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| ES2258527T3 (es) | 2000-05-05 | 2006-09-01 | Bayer Technology Services Gmbh | Nanoparticulas impurificadas como biomarcadores. |
| WO2002029410A2 (en) | 2000-10-06 | 2002-04-11 | Quantum Dot Corporation | Cells having a spectral signature, and methods of preparation and use thereof |
| BR0115127A (pt) | 2000-11-20 | 2004-02-17 | Oncolytics Biotech Inc | Método de fornecer um vìrus a um tumor sólido para reduzir crescimento do tumor |
| US20020127224A1 (en) | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
| US6756063B2 (en) | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
| DE10154016B4 (de) | 2001-10-26 | 2004-02-12 | Berlin Heart Ag | Magnetflüssigkeit und Verfahren zur ihrer Herstellung |
| AU2002351240A1 (en) | 2002-03-08 | 2003-09-22 | James Hainfeld | Gold nanoparticles used for x-rays imaging |
| US20030191458A1 (en) | 2002-04-03 | 2003-10-09 | Cornelius Diamond | Light-activated drug delivery method and device |
| US7769423B2 (en) | 2002-09-11 | 2010-08-03 | Duke University | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting |
| US20030125283A1 (en) | 2002-09-16 | 2003-07-03 | Gatenby Robert A. | Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents |
| CA2513759C (en) | 2003-01-24 | 2014-05-13 | The Research Foundation Of State University Of New York | Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same |
| US7235228B2 (en) | 2003-04-15 | 2007-06-26 | The United States Of America As Represented By The Secretary Of The Navy | Fluorescent-magnetic nanoparticles with core-shell structure |
| US20050084869A1 (en) | 2003-10-20 | 2005-04-21 | Sung Hyun Kim | Novel composition and methods for the diagnosis of lung cancer |
| US20050090732A1 (en) | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| JP2007511503A (ja) | 2003-11-17 | 2007-05-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 医療画像化技術用の造影剤及びその使用 |
| AU2004308756B2 (en) | 2003-12-22 | 2010-06-24 | Bracco Suisse S.A. | Gas-filled microvesicle assembly for contrast imaging |
| US20080193372A1 (en) | 2004-02-10 | 2008-08-14 | Barnes-Jewish Hospital | Efficacy and Safety of Targeted Particulate Agents with Decoy Systems |
| JP4895151B2 (ja) | 2004-02-27 | 2012-03-14 | 日立金属株式会社 | 鉄系ナノサイズ粒子およびその製造方法 |
| FR2869803B1 (fr) | 2004-05-10 | 2006-07-28 | Nanobiotix Sarl | Particules activables, preparation et utilisations |
| US20050260137A1 (en) | 2004-05-18 | 2005-11-24 | General Electric Company | Contrast agents for magnetic resonance imaging |
| US20070031337A1 (en) | 2004-06-22 | 2007-02-08 | Reinhard Schulte | Nanoparticle enhanced proton computed tomography and proton therapy |
| GB2415374A (en) | 2004-06-25 | 2005-12-28 | Leuven K U Res & Dev | Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles |
| WO2006037081A2 (en) | 2004-09-28 | 2006-04-06 | The Regents Of The University Of California | Nanoparticle radiosensitizers |
| FR2877571B1 (fr) | 2004-11-05 | 2007-04-13 | Nanobiotix Sarl | Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations |
| JP5082446B2 (ja) | 2004-11-10 | 2012-11-28 | コニカミノルタエムジー株式会社 | 被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム |
| US20060264804A1 (en) | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
| FR2884149B1 (fr) | 2005-04-12 | 2007-06-08 | Henri Mehier | Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal |
| US20070092927A1 (en) | 2005-06-13 | 2007-04-26 | University Of Dayton | Photocatalytic particles with directed and controlled redox activity |
| DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| WO2007052267A2 (en) | 2005-11-01 | 2007-05-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Biodegradable composite for internal local radiotherapy |
| US20070098641A1 (en) | 2005-11-02 | 2007-05-03 | General Electric Company | Nanoparticle-based imaging agents for X-ray/computed tomography |
| KR100745744B1 (ko) | 2005-11-11 | 2007-08-02 | 삼성전기주식회사 | 나노 입자 코팅 방법 |
| WO2007122956A1 (ja) | 2006-03-24 | 2007-11-01 | Toto Ltd. | 酸化チタン複合体粒子、その分散液、およびそれらの製造方法 |
| WO2007116954A2 (en) | 2006-03-30 | 2007-10-18 | Fujifilm Corporation | Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer |
| EP1852107A1 (en) | 2006-04-19 | 2007-11-07 | Nanobiotix | Magnetic nanoparticles compositions and uses thereof |
| US20090181076A1 (en) | 2006-05-04 | 2009-07-16 | University Of South Australia | Drug Release From Nanoparticle-Coated Capsules |
| RU2009104312A (ru) | 2006-07-10 | 2010-08-20 | Конинклейке Филипс Электроникс Н.В. (Nl) | Наночастицы типа "ядро-оболочка" для терапии и диагностических целей |
| DE102006041495A1 (de) | 2006-08-29 | 2008-03-20 | Friedrich-Schiller-Universität Jena | Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung |
| NO329127B1 (no) | 2006-09-12 | 2010-08-30 | Epitarget As | Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel |
| NO20064315L (no) | 2006-09-22 | 2008-03-24 | Epitarget As | T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav |
| IL181126A0 (en) | 2006-11-01 | 2007-07-04 | S B Biotechnologies Ltd | Preparation of gold-containing nano-liposome particles and their use in medical therapy |
| EP1920784A1 (en) | 2006-11-13 | 2008-05-14 | Koninklijke Philips Electronics N.V. | Radiation sensitizers in ionizing radiation therapy and imaging |
| US20090004258A1 (en) | 2007-06-27 | 2009-01-01 | National Health Research Institutes | Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field |
| EA201070296A1 (ru) | 2007-08-21 | 2010-08-30 | Алза Корпорейшн | Липосомные композиции для введения in vivo соединений бороновой кислоты |
| JP2009067613A (ja) | 2007-09-11 | 2009-04-02 | Fujifilm Corp | コア−シェル型金属酸化物微粒子及びその製造方法 |
| US20120176016A1 (en) | 2007-09-28 | 2012-07-12 | General Electric Company | Core-shell particulates, articles, and method of making |
| FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
| EP2067485A1 (en) | 2007-12-07 | 2009-06-10 | Koninklijke Philips Electronics N.V. | Drug carrier providing MRI contrast enhancement |
| EP2231765A2 (en) | 2007-12-21 | 2010-09-29 | University Of Guelph | Polysaccharide nanoparticles |
| DE102008003615A1 (de) | 2008-01-09 | 2009-07-16 | Magforce Nanotechnologies Ag | Magnetische Transducer |
| DE102008008522A1 (de) | 2008-02-11 | 2009-08-13 | Magforce Nanotechnologies Ag | Implantierbare Nanopartikel-enthaltende Produkte |
| WO2009105774A2 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| DE102008000852A1 (de) | 2008-03-27 | 2009-10-01 | Bosch Mahle Turbo Systems Gmbh & Co. Kg | Abgasturbolader für ein Kraftfahrzeug |
| WO2009142754A1 (en) | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
| EP2130553A1 (en) | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| US20130023714A1 (en) | 2008-10-26 | 2013-01-24 | Board Of Regents, The University Of Texas Systems | Medical and Imaging Nanoclusters |
| US8395131B2 (en) | 2009-06-20 | 2013-03-12 | Xiaodong Wu | Method for three dimensional (3D) lattice radiotherapy |
| EP2275137A1 (en) | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
| EP2305310A1 (en) | 2009-09-25 | 2011-04-06 | Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE | Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents |
| GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| EP3960215B1 (en) | 2009-12-15 | 2024-10-16 | Incept, LLC | Implants and biodegradable fiducial markers |
| CN102781472B (zh) | 2010-02-17 | 2014-07-02 | 国立大学法人神户大学 | 放射线治疗剂 |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| WO2011133228A2 (en) | 2010-04-23 | 2011-10-27 | Pixelligent Technologies, Llc | Synthesis, capping and dispersion of nanocrystals |
| GB201009455D0 (en) | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| WO2012009406A2 (en) | 2010-07-13 | 2012-01-19 | University Of Utah Research Foundation | Gold particles and methods of making and using the same in cancer treatment |
| EP2624874A4 (en) | 2010-10-08 | 2014-04-02 | Univ Texas | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| WO2012051220A1 (en) | 2010-10-11 | 2012-04-19 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| US20140227343A1 (en) | 2011-01-31 | 2014-08-14 | Centre National De La Recherche Scientifique | Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles |
| CN103429227B (zh) | 2011-01-31 | 2017-12-19 | 纳米生物技术公司 | 纳米粒子递送系统、其制备及应用 |
| JP2014516960A (ja) * | 2011-05-19 | 2014-07-17 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ヒトｈｅｒ３抗体及びその使用 |
| US10251841B2 (en) | 2011-10-17 | 2019-04-09 | Trustees Of Boston University | Polymeric depots for localization of agent to biological sites |
| US10064960B2 (en) | 2011-11-25 | 2018-09-04 | Danmarks Tekniske Universitet | Formulation of solid nano-sized particles in a gel-forming system |
| MX362089B (es) | 2011-12-16 | 2019-01-07 | Nanobiotix | Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos. |
| IN2014MN02089A (enExample) | 2012-03-20 | 2015-09-11 | Einstein Coll Med | |
| WO2014039874A2 (en) | 2012-09-07 | 2014-03-13 | Carnegie Mellon University | Methods and materials for reducing reticuloendothelial system clearance of particles from a subject |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140213765A1 (en) | 2013-01-25 | 2014-07-31 | I-Liang Lee | Albumin tissue scaffold |
| CA2897362C (en) | 2013-01-25 | 2023-02-14 | Nanobiotix | Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer |
| US20140219926A1 (en) | 2013-02-01 | 2014-08-07 | The Trustees Of Dartmouth College | Biodegradable Iron Oxide Nanoparticle Gel for Tumor Bed Therapy |
| BR112015029853A2 (pt) | 2013-05-30 | 2017-07-25 | Nanobiotix | uso de uma composição farmacêutica |
| MA38709A1 (fr) | 2013-06-20 | 2018-05-31 | Nanobiotix | Compositions et procédés pour une utilisation en diagnostic médical |
| AU2014283232B2 (en) | 2013-06-20 | 2019-03-28 | Nanobiotix | Compositions and methods for use in oncology |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| CA2968473A1 (en) | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| PT3229776T (pt) | 2014-11-25 | 2023-08-17 | Curadigm Sas | Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações |
| JP6789960B2 (ja) | 2014-11-25 | 2020-11-25 | キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ | 医薬組成物、その調製及び使用 |
| PL3229843T3 (pl) | 2014-11-25 | 2020-06-29 | Curadigm Sas | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji |
| LT3223796T (lt) | 2014-11-25 | 2021-10-25 | Curadigm Sas | Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai |
-
2016
- 2016-05-27 EA EA201792560A patent/EA201792560A1/ru unknown
- 2016-05-27 KR KR1020177037576A patent/KR102727195B1/ko active Active
- 2016-05-27 CN CN202410296710.7A patent/CN118286421A/zh active Pending
- 2016-05-27 CA CA2987331A patent/CA2987331A1/en active Pending
- 2016-05-27 US US15/577,482 patent/US11096962B2/en active Active
- 2016-05-27 UA UAA201712689A patent/UA124572C2/uk unknown
- 2016-05-27 WO PCT/EP2016/061989 patent/WO2016189125A1/en not_active Ceased
- 2016-05-27 MA MA043100A patent/MA43100A/fr unknown
- 2016-05-27 AU AU2016269146A patent/AU2016269146B2/en active Active
- 2016-05-27 MX MX2017015424A patent/MX2017015424A/es unknown
- 2016-05-27 AR ARP160101554A patent/AR104806A1/es unknown
- 2016-05-27 CN CN201680038140.5A patent/CN107708668A/zh active Pending
- 2016-05-27 JP JP2017561738A patent/JP2018516256A/ja active Pending
- 2016-05-27 HK HK18105609.2A patent/HK1246160A1/zh unknown
- 2016-05-27 TW TW105116729A patent/TWI873079B/zh active
- 2016-05-27 EP EP16727391.1A patent/EP3302419A1/en active Pending
- 2016-05-27 BR BR112017025553A patent/BR112017025553A2/pt not_active Application Discontinuation
- 2016-05-27 NZ NZ738527A patent/NZ738527A/en unknown
- 2016-05-27 TW TW112126400A patent/TW202417036A/zh unknown
-
2017
- 2017-11-22 IL IL255853A patent/IL255853B/en active IP Right Grant
- 2017-11-28 MX MX2023007706A patent/MX2023007706A/es unknown
- 2017-12-20 ZA ZA2017/08686A patent/ZA201708686B/en unknown
-
2021
- 2021-04-27 AU AU2021202582A patent/AU2021202582B2/en active Active
- 2021-07-29 US US17/388,066 patent/US20210353670A1/en not_active Abandoned
-
2023
- 2023-03-28 JP JP2023051686A patent/JP7570134B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023082080A5 (enExample) | ||
| Reali et al. | IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines | |
| Xiong et al. | Advanced treatment in high-grade gliomas | |
| US20210353670A1 (en) | Nanoparticles for use as a therapeutic vaccine | |
| Minnar et al. | Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine | |
| EP2337579A1 (en) | Cancer treatments with radiation and immunocytokines | |
| Maletzki et al. | Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer | |
| Salewski et al. | Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors | |
| Pieper et al. | Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models | |
| Sharon et al. | Immunotherapy in head and neck squamous cell carcinoma: a narrative review | |
| Radosa et al. | Clinical data on immunotherapy in breast cancer | |
| Rafiq et al. | Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects | |
| Olivera et al. | Regional and intratumoral adoptive T-cell therapy | |
| US20230190934A1 (en) | Methods and compositions for treating a tumor | |
| US20180319861A1 (en) | Combination therapy for malignant diseases | |
| CN104906575A (zh) | LSECtin作为黑色素瘤免疫治疗的靶点 | |
| Hoesli et al. | Immunotherapy for head and neck squamous cell carcinoma | |
| JP2023549698A (ja) | がんの治療のためのナノ粒子の組成物 | |
| Huang et al. | Development of membrane-bound GM-CSF and IL-18 as an effective tumor vaccine | |
| Kong et al. | Combating cancer immunotherapy resistance: a nano‐medicine perspective | |
| Hu et al. | 200 NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model | |
| Jensen et al. | CarboCell combinatorial immunotherapy orchestrates curative anticancer immune activation of the tumor microenvironment | |
| NZ776598B2 (en) | Nanoparticles for use as a therapeutic vaccine | |
| Moorthy et al. | Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer | |
| JP2018533915A (ja) | 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用 |